---
id: 120
title: Cytomegalovirus (CMV) in Immunocompromised Hosts
category: organisms
subcategory: viruses
tags: [CMV, cytomegalovirus, ganciclovir, valganciclovir, retinitis, transplant]
difficulty: medium
---

## Question

How is CMV managed in immunocompromised hosts? Use the **"Valganciclovir for Prophylaxis/Mild, IV Ganciclovir for Severe"** framework.

## Answer

### **CMV Syndromes by Host:**

**Transplant Recipients:**
- **Pneumonitis**, **colitis/enteritis**, **hepatitis**, **retinitis**
- **Highest risk:** **D+/R-** (donor CMV+, recipient CMV-)

**HIV/AIDS (CD4 <50):**
- **Retinitis** (most common), colitis, esophagitis, encephalitis, pneumonitis

**Immunocompetent:**
- **CMV mononucleosis** (similar to EBV mono but heterophile-negative)

### **Treatment by Syndrome:**

| Syndrome | Induction Therapy | Maintenance Therapy | Duration |
|----------|-------------------|---------------------|----------|
| **CMV retinitis (AIDS)** | **Valganciclovir 900mg PO BID** × 14-21 days OR **ganciclovir 5 mg/kg IV q12h** | **Valganciclovir 900mg daily** | Until immune reconstitution (CD4 >100 × 3-6 months on ART) |
| **CMV colitis/pneumonitis (transplant)** | **Ganciclovir 5 mg/kg IV q12h** × 14-21 days | **Valganciclovir 900mg daily** | Until CMV PCR negative × 2 weeks (typically 3-6 weeks total) |
| **CMV viremia (asymptomatic)** | **Valganciclovir 900mg BID** × 14-21 days | Consider maintenance if high-risk | Until CMV PCR negative |

### **Prophylaxis (Transplant):**

**High-Risk (D+/R-):**
- **Valganciclovir 900mg PO daily** × **3-6 months** post-transplant (adjust for renal function)

**Intermediate-Risk (R+):**
- **Preemptive therapy:** Monitor CMV PCR weekly → treat if detected (valganciclovir 900mg BID × 2-3 weeks)

**Low-Risk (D-/R-):**
- No prophylaxis

### **Alternative Agents:**

| Drug | Indication | Dosing | Notes |
|------|------------|--------|-------|
| **Foscarnet** | **Ganciclovir-resistant CMV** | **90 mg/kg IV q12h** (induction) → **90-120 mg/kg daily** (maintenance) | **Nephrotoxic**, electrolyte abnormalities (↓Ca, ↓Mg, ↓K) |
| **Cidofovir** | Ganciclovir-resistant | **5 mg/kg IV weekly × 2** → **5 mg/kg every 2 weeks** | **Highly nephrotoxic** (give with probenecid + saline hydration) |

## Key Points

### **CMV Retinitis (HIV/AIDS):**
- **"Pizza pie" or "cottage cheese and ketchup" fundus appearance**
- **Hemorrhages + fluffy white infiltrates** along retinal vessels
- **Painless vision loss**
- **Ophthalmology consult** required
- **Start ART** (immune reconstitution critical)
- **Immune reconstitution inflammatory syndrome (IRIS):** CMV retinitis may worsen transiently after starting ART

### **Diagnosis:**
- **CMV PCR (quantitative):** Detects viremia (used for monitoring, preemptive therapy)
- **Tissue biopsy:** Gold standard for end-organ disease (CMV inclusion bodies, "owl's eye" inclusions)
- **Serology (IgG/IgM):** Used for donor/recipient risk stratification (not for diagnosis of active disease)

### **Ganciclovir Toxicity:**
- **Myelosuppression** (neutropenia, thrombocytopenia) - dose-dependent
- **Monitor CBC weekly** during induction, every 2 weeks during maintenance
- **Renal toxicity** (less than foscarnet/cidofovir)
- **Teratogenic**, **carcinogenic** (handle with care)

### **Resistance:**
- **Mechanisms:** UL97 mutation (ganciclovir kinase), UL54 mutation (DNA polymerase)
- **Suspect if:** Persistent viremia despite therapy, progressive disease
- **Treatment:** **Foscarnet** (first-line for resistance) ± **cidofovir** (if foscarnet-resistant)

### **Clinical Pearls:**
- **CMV D+/R-:** Highest risk → valganciclovir prophylaxis × 3-6 months
- **Retinitis:** Valganciclovir 900mg BID (induction) → daily (maintenance until CD4 >100 × 3-6 months)
- **Severe/end-organ disease:** IV ganciclovir 5 mg/kg q12h
- **Resistance:** Foscarnet 90 mg/kg IV q12h (nephrotoxic)
- **Monitor CMV PCR** to guide duration (treat until negative × 2 weeks)
- **Immune reconstitution (ART)** critical for CMV retinitis cure

## Sources

- [IDSA: CMV Guidelines in Transplantation 2024]
- [OI Guidelines: CMV in HIV/AIDS 2023]

## Media

N/A
